Theralase® to Host Investor Conference Call Today to Discuss Phase III Data
TORONTO,ON – January 30,2024 – Theralase Technologies Inc. (TSXV: TLT), a clinical-stage biopharmaceutical company, is reminding investors of a conference call scheduled for today, January 30, 2024, at 11:00 a.m. Eastern Time to discuss the topline data from its phase III Photodynamic Therapy (PDT) for non-muscle invasive bladder cancer trial.
The call will provide an update on the trial’s results, which evaluated the safety and efficacy of Theralase-525, the Company’s lead photoactive compound, in patients with Bacillus Calmette-Guérin (BCG)-refractory non-muscle invasive bladder cancer. Management will discuss the findings and answer questions from investors. This data is critical as BCG is the standard of care treatment,and a meaningful portion of patients become refractory to it,creating a substantial unmet medical need. The call’s outcome could significantly impact Theralase’s future development plans and potential market opportunities.
Conference Call Details:
* Date: January 30, 2024
* Time: 11:00 a.m. Eastern Time
* Dial-in Number: 1-877-407-0792
* International Dial-in Number: 1-201-689-8562
* Conference ID: 13740398
* Webcast Link: https://api.newsfilecorp.com/redirect/VvY51iP8Vx
Investors can access a replay of the call following the live event. For investor inquiries, contact Kristina Hachey, CPA, Chief Financial Officer at khachey@theralase.com or reach out via the company website: https://api.newsfilecorp.com/redirect/zApmXi835B.
Company Contact:
Kristina Hachey, CPA
Chief Financial Officer
1-866-THE-LASE (843.5273)
416-699-LASE (5273) X 224
khachey@theralase.com
